Balchem vs Hawkins
BCPC and HWKN side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCPC and HWKN compare
Balchem is the larger company, worth 1.7 times as much as Hawkins ($5.4B against $3.1B).
On earnings, Balchem is cheaper: it trades at 31.9× trailing earnings, against 36.0× for Hawkins.
Balchem grew revenue faster over the last twelve months (9.4% versus 9.0% for Hawkins).
Balchem keeps more of each dollar of sales as profit, with a net margin of 15.4% compared with 7.5% at Hawkins.
Both pay dividends: Balchem yields 0.57% and Hawkins 0.53%.
Balchem scores higher on the StockData Score (19 against 14 for Hawkins), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCPC | HWKN |
|---|---|---|
| Size and price | ||
| Market cap | $5.4B | $3.1B |
| Share price | $169.63 | $148.50 |
| Change, 1 year | 8.2% | 17.4% |
| Change, 5 years | 2.6% | 340% |
| Beta (5Y) | 0.14 | −0.25 |
| Employees | 1,352 | 1,200 |
| StockData Score | ||
| Total score | 19 (better) | 14 |
| Valuation score | 2 (better) | 0 |
| Growth score | 4 (better) | 2 |
| Performance score | 5 | 6 (better) |
| Health score | 6 (better) | 3 |
| Dividend score | 2 | 3 (better) |
| Valuation | ||
| P/E | 31.9× (better) | 36.0× |
| P/S | 4.9× | 2.7× (better) |
| P/B | 4.1× (better) | 5.5× |
| EV/EBITDA | 19.1× | 18.2× (better) |
| P/FCF | – | 33.4× |
| PEG | 2.37 (better) | 3.28 |
| FCF yield | – | 3.0% |
| Fair value | $148.59 | $91.81 |
| Margin of safety | −14.2% (better) | −61.7% |
| Growth | ||
| Revenue growth (TTM) | 9.4% (better) | 9.0% |
| Revenue growth, 5Y average | 8.1% | 12.7% (better) |
| Net income growth (TTM) | 14.5% (better) | 3.2% |
| EPS growth (TTM) | 16.2% (better) | 3.5% |
| EPS growth, 5Y average | 12.8% | 15.2% (better) |
| Profitability | ||
| Gross margin | 36.5% (better) | 22.4% |
| Operating margin | 20.7% (better) | 11.1% |
| Net margin | 15.4% (better) | 7.5% |
| FCF margin | – | 8.1% |
| Return on equity | 13.0% | 16.0% (better) |
| Return on invested capital | 14.3% (better) | 12.8% |
| Financial health | ||
| Debt / equity | 0.00 | 0.41 (better) |
| Net debt / EBITDA | – | 1.22 |
| Current ratio | 2.47 (better) | 2.28 |
| Altman Z-score | 10.88 (better) | 6.60 |
| Piotroski F-score | 9 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.57% (better) | 0.53% |
| Payout ratio | 18.0% | 18.7% |
| Years of dividend growth | 3 | 7 (better) |
| Dividend growth, 5Y average | – | 9.7% |
| Buyback yield | 2.3% (better) | 0.60% |
| Shareholder yield | 2.9% (better) | 1.1% |
| Ownership | ||
| Held by institutions | 91.3% | 78.3% |
| Held by insiders | 0.72% | 4.2% |
| Insider net buying, 12 months | −$2.2M | $650K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 1.6% | 6.5% |
Go deeper
- BCPC stock overview
- BCPC income statement
- BCPC valuation and score
- HWKN stock overview
- HWKN income statement
- HWKN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.